Retroviruses human immunodeficiency virus and murine leukemia virus are enriched in phosphoinositides.
Retroviruses acquire a lipid envelope during budding from the membrane of their hosts. Therefore, the composition of this envelope can provide important information about the budding process and its location. Here, we present mass spectrometry analysis of the lipid content of human immunodeficiency virus type 1 (HIV-1) and murine leukemia virus (MLV). The results of this comprehensive survey found that the overall lipid content of these viruses mostly matched that of the plasma membrane, which was considerably different from the total lipid content of the cells. However, several lipids are enriched in comparison to the composition of the plasma membrane: (i) cholesterol, ceramide, and GM3; and (ii) phosphoinositides, phosphorylated derivatives of phosphatidylinositol. Interestingly, microvesicles, which are similar in size to viruses and are also released from the cell periphery, lack phosphoinositides, suggesting a different budding mechanism/location for these particles than for retroviruses. One phosphoinositide, phosphatidylinositol 4,5-bisphosphate [PI(4,5)P(2)], has been implicated in membrane binding by HIV Gag. Consistent with this observation, we found that PI(4,5)P(2) was enriched in HIV-1 and that depleting this molecule in cells reduced HIV-1 budding. Analysis of mutant virions mapped the enrichment of PI(4,5)P(2) to the matrix domain of HIV Gag. Overall, these results suggest that HIV-1 and other retroviruses bud from cholesterol-rich regions of the plasma membrane and exploit matrix/PI(4,5)P(2) interactions for particle release from cells.
Chan
Robin
R
Centre for Life Sciences (CeLS), Yong Loo Lin School of Medicine, National University of Singapore, 28 Medical Drive, Level 04-21, Singapore 117607, Singapore.
Uchil
Pradeep D
PD
Jin
Jing
J
Shui
Guanghou
G
Ott
David E
DE
Mothes
Walther
W
Wenk
Markus R
MR
D000818:Animals; D002460:Cell Line; D002462:Cell Membrane / Q000737:chemistry; D003593:Cytoplasm / Q000737:chemistry; D015497:HIV-1 / Q000737:chemistry*; D006801:Humans; D009052:Leukemia Virus, Murine / Q000737:chemistry*; D008055:Lipids / Q000032:analysis*; D013058:Mass Spectrometry; D010716:Phosphatidylinositols / Q000302:isolation & purification*; D051381:Rats; D022142:Secretory Vesicles / Q000737:chemistry; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000737:chemistry / Q000235:genetics
D008055:Lipids; D010716:Phosphatidylinositols; D054301:gag Gene Products, Human Immunodeficiency Virus
J Cell Biol. 1987 Sep;105(3):1227-40
2821012
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2339-44
9122196
Traffic. 2003 Nov;4(11):785-801
14617360
J Cell Biol. 2005 Jul 18;170(2):317-25
16027225
J Biol Chem. 1980 Oct 10;255(19):9044-50
6251073
J Biol Chem. 1998 Aug 7;273(32):20121-7
9685355
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13523-5
11095714
Biochim Biophys Acta. 1985 Dec 5;821(2):264-76
4063367
J Virol. 2007 Aug;81(15):7873-84
17522207
Virology. 1971 Oct;46(1):106-16
4108030
J Lipid Res. 2007 Sep;48(9):1976-84
17565170
J Biol Chem. 2003 Mar 28;278(13):10963-72
12519789
PLoS Biol. 2006 Oct;4(11):e365
17076584
J Cell Sci. 1992 Sep;103 ( Pt 1):39-51
1331135
Biochim Biophys Acta. 2006 Aug;1761(8):897-912
16938488
J Virol. 1995 Apr;69(4):2443-50
7884892
Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11364-9
16840558
Can J Biochem Physiol. 1959 Aug;37(8):911-7
13671378
Virology. 2007 Mar 30;360(1):27-35
17095032
J Virol. 2003 Dec;77(23):12699-709
14610192
J Biol Chem. 2001 Jun 8;276(23):20589-96
11279185
Structure. 2005 Oct;13(10):1521-31
16216583
Nat Immunol. 2006 Nov;7(11):1139-42
17053798
J Gen Virol. 2003 Apr;84(Pt 4):757-768
12655075
Biochim Biophys Acta. 2005 Dec 30;1746(3):284-94
16226325
Annu Rev Cell Dev Biol. 2004;20:395-425
15473846
Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5181-5
8389472
Nat Methods. 2006 Apr;3(4):251-8
16554828
Science. 2008 Feb 29;319(5867):1244-7
18309083
J Biol Chem. 2004 Mar 12;279(11):9997-10004
14699154
Curr Biol. 2001 Jun 5;11(11):875-9
11516650
Nat Rev Microbiol. 2007 Apr;5(4):253-63
17325726
Science. 2006 Dec 1;314(5804):1458-61
17095657
J Cell Sci. 2005 Mar 15;118(Pt 6):1099-102
15764592
Virology. 1972 Nov;50(2):550-7
4344196
Nat Rev Mol Cell Biol. 2006 Jan;7(1):9-19
16365634
J Virol. 2006 Jun;80(11):5292-300
16699009
J Virol. 1995 Jun;69(6):3949-54
7745752
J Virol. 2007 May;81(10):5294-304
17344303
J Cell Biol. 2008 Feb 11;180(3):473-82
18250201
Science. 2006 Jul 21;313(5785):347-51
16857939
Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15452-7
15489273
J Virol. 2007 Jul;81(14):7476-90
17507489
Nat Biotechnol. 2003 Jul;21(7):813-7
12808461
J Cell Biol. 2006 Jun 5;173(5):795-807
16735575
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2641-6
16481622
J Lipid Res. 2005 Aug;46(8):1678-91
15863835
PLoS Pathog. 2007 Mar;3(3):e36
17381240
J Cell Biol. 2007 Apr 23;177(2):329-41
17438075
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7152-7
11416200
Methods. 2005 Jun;36(2):207-24
15894491
J Virol. 2005 Apr;79(7):4055-65
15767407
J Virol. 2008 Mar;82(5):2405-17
18094158
Biophys J. 2004 Apr;86(4):2188-207
15041659
Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14889-94
15465916
J Virol. 2001 Jun;75(11):4973-83
11333876
J Virol. 2007 Jun;81(12):6434-45
17392361
J Cell Biol. 2007 Mar 26;176(7):953-64
17371834
PLoS Biol. 2006 Dec;4(12):e435
17147474
EMBO J. 2005 Sep 21;24(18):3159-65
16138081
J Virol. 2000 Apr;74(7):3264-72
10708443
J Virol. 2000 Sep;74(18):8358-67
10954535
Adv Virus Res. 2005;64:311-58
16139599